Navigation Links
Masimo Initiates Full Market Release of First-Ever Noninvasive Continuous Hemoglobin Monitor
Date:3/24/2009

Hospital Center of Poitiers in Poitiers, France believes the combination of SpHb and PVI may prove to have significant clinical benefits, saying that "SpHb, along with PVI, have been important improvements for both the department and our patients. The ability to track hemoglobin and fluid volume in real-time allows us to be more precise in our clinical routine."

SpHb is part of the Masimo Rainbow SET Pulse CO-Oximetry patient monitoring platform -- the first-and-only upgradable technology platform capable of continuously and noninvasively measuring multiple blood constituents and helping to predict fluid responsiveness in patients previously requiring invasive procedures. Masimo Rainbow SET noninvasive measurements -- including: total hemoglobin (SpHb(TM)), oxygen content (SpOC(TM)), carboxyhemoglobin (SpCO(R)), methemoglobin (SpMet(R)), PVI(TM), oxyhemoglobin (SpO2), pulse rate (PR), and perfusion index (PI) -- have the potential to facilitate faster, easier and safer health decisions.

Currently available in bedside Masimo Radical-7(R) and Rad-87(R) Pulse CO-Oximeter patient monitors, SpHb will also be offered in handheld monitors and select multiparameter patient monitoring brands through Masimo Rainbow SET Pulse CO-Oximetry technology license agreements.

Joe Kiani, Founder and CEO of Masimo said, "SpHb's success during the limited market release phase at hospitals around the world illustrates its expected significant impact on clinical practice and patient care. In addition and as we expected, our limited market release program provided us with the opportunity to enhance the robustness in low perfusion situations and broaden the cross section of individuals on which the technology performs. The ability for clinicians in hospitals, private practices, and other healthcare settings to perform immediate and continuous noninvasive hemoglobin monitoring creates new opportunities to save lives, optimize decision
'/>"/>

SOURCE Masimo
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. New Multi-Center Study Finds Masimo SET Pulse Oximetry Screening Significantly Improves Detection of Congenital Heart Disease in Newborns
2. AARC Presentation Cites Masimo Patient SafetyNet as Key Factor in Improving Patient Outcomes and Reducing Costs in Post-Acute Care Facilities
3. Masimo Reports Third Quarter 2008 Financial Results
4. New Clinical Studies Presented at the American Society of Anesthesiology (ASA) Annual Meeting Show Masimo Technologies Provide Advanced Clinical Intelligence
5. Five New Clinical Studies Show Value of Masimo PVI & PI
6. Masimo to Report Third Quarter 2008 Financial Results on October 27, 2008
7. Masimo Initiates Limited Release of First-Ever Noninvasive and Continuous Hemoglobin Monitors
8. Masimo Announces Desaturation Index 3D Alarm as Standard Feature in All Radical-7 Pulse CO-Oximetry Devices
9. Masimo to Present at Goldman Sachs 29th Annual Global Healthcare Conference
10. Masimo to Present at Deutsche Bank 33rd Annual Health Care Conference
11. Masimo Reports First Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... Louis, MO (PRWEB) August 21, 2014 ... full service biopharmaceutical contract development and manufacturing organization ... by Progenics Pharmaceuticals, Inc., an oncology company focused ... and treating cancer, to manufacture the anti-prostate specific ... PSMA ADC product candidate. Under the agreement ...
(Date:8/20/2014)... analysis of patented university inventions licensed to biotechnology ... to commercialization. To open these roadblocks, the researchers ... during the discovery stage could lead to faster ... frequently derived from discoveries made in university laboratories ... known during clinical trials, which have a high ...
(Date:8/20/2014)... Livermore, California (PRWEB) August 20, 2014 ... to develop and apply the most complete climate ... challenging and demanding climate change issues. , Eight ... combining forces with the National Center for Atmospheric ... in the new effort. Other participating national laboratories ...
(Date:8/20/2014)... Not long ago, it was more ... performed late in the development cycle – even after ... trends suggest that, like many things GxP, expectations for ... years, multiple drug sponsors have been required by authorities ... during phase I/II. It’s not only clinical trial material ...
Breaking Biology Technology:Gallus Enters Agreement with Progenics Pharmaceuticals, Inc. for Manufacture of Anti-PSMA Monoclonal Antibody 2Gallus Enters Agreement with Progenics Pharmaceuticals, Inc. for Manufacture of Anti-PSMA Monoclonal Antibody 3Early bottlenecks in developing biopharmaceutical products delay commercialization 2Early bottlenecks in developing biopharmaceutical products delay commercialization 3New Project Is the ACME of Addressing Climate Change 2New Project Is the ACME of Addressing Climate Change 3Are Extractable and Leachables going Phase-Appropriate? New Webinar Hosted by Xtalks 2
... Dec. 9 BioMarin Pharmaceutical,Inc. (Nasdaq: ... partner Merck Serono, a division,of Merck KGaA, ... (sapropterin dihydrochloride) for the treatment of,hyperphenylalaninemia (HPA) ... the European Commission. Merck Serono estimates ...
... DCTH ) today announced the appointment of Roger G. ... Executive Chairman of Cortex Pharmaceuticals, Inc. (Amex: COR ), ... disorders. , , (Logo: ... Prior to joining Cortex, Dr. Stoll worked as a consultant ...
... Md., Dec. 9 EntreMed, Inc.,(Nasdaq: ... the treatment of cancer and inflammatory diseases, today,announced ... of ENMD-2076 in refractory,multiple myeloma patients. The study ... Melvin and Bren Simon Cancer Center, Indianapolis, Indiana. ...
Cached Biology Technology:Kuvan Receives Marketing Approval in the European Union 2Kuvan Receives Marketing Approval in the European Union 3Kuvan Receives Marketing Approval in the European Union 4Delcath Adds Senior Pharmaceutical Professional to Its Board of Directors 2Delcath Adds Senior Pharmaceutical Professional to Its Board of Directors 3EntreMed Initiates ENMD-2076 Clinical Trial in Multiple Myeloma 2EntreMed Initiates ENMD-2076 Clinical Trial in Multiple Myeloma 3EntreMed Initiates ENMD-2076 Clinical Trial in Multiple Myeloma 4
(Date:8/20/2014)... finds life can persist in a cold, dark world. ... team that examined waters and sediments from a shallow ... the extreme environment supports microbial ecosystems. , The ... colleagues has implications for life in other extreme environments, ... findings are published in the current edition of the ...
(Date:8/20/2014)... in in this image of the Para and Mato ... most likely intentionally set in order to deforest the ... stand of trees where the land is thereafter converted ... of forestland to farms, ranches, or urban use. The ... the Amazon Rainforest in the middle of the image ...
(Date:8/20/2014)... Health has awarded the Oklahoma Medical Research Foundation a ... anthrax and the bacteria,s effects on humans. , ... his colleagues have studied the human immune response to ... Human Immunology. The original funding came soon after anthrax-laced ... of the terrorist attacks of Sept. 11, 2001. ...
Breaking Biology News(10 mins):University of Tennessee research uncovers subglacial life beneath Antarctic ice sheet 2$14.5 million grant awarded to continue anthrax studies 2
... Rome, Italy: Researchers have developed a way of accurately ... blood test. The average difference between the predicted age and ... the menopause was only a third of a year, and ... years. Dr Fahimeh Ramezani Tehrani will tell the 26th ...
... new technology that allows scientists to monitor how individual cells ... researchers have uncovered a much larger spectrum of differences between ... act in a uniform fashion, as was previously thought. ... Markus Covert, PhD, assistant professor of bioengineering and senior author ...
... 27th, 2010 The Elsevier Foundation, TWAS and TWOWS ... scientists from Africa, the Middle East, Asia, Latin America ... was made at the Third World Organization for Women ... Women Scientists in a Changing World, hosted by the ...
Cached Biology News:Researchers develop accurate way to predict the age when women will hit the menopause 2Researchers develop accurate way to predict the age when women will hit the menopause 3Same types of cell respond differently to stimulus, Stanford study shows 2Same types of cell respond differently to stimulus, Stanford study shows 312 women scientists announced as winners of Elsevier Foundation TWOWS Awards 2
... Ambion's custom siRNA service provides the premium ... silencing research. Custom siRNAs can be readily ... base target sequence, or by providing the ... out Ambion's Silencer Validated and Silencer Pre-designed ...
, Premium quality synthesis and purification , You provide the sequence, we'll do the rest , Rigorous quality control , Your choice of purification method, amount and format , Available annealed...
, Premium quality synthesis and purification , You provide the sequence, we'll do the rest , Rigorous quality control , Your choice of purification method, amount and format , Available annealed...
Human TGF-beta RIIb Affinity Purified Polyclonal Ab...
Biology Products: